Abstract
The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study). Between January 2009 and April 2012, a total of 497 patients were enrolled from 11 sites in Korea. Of these, 482 patients were evaluable for safety analyses. Case report forms of paper or electronic version were used to record safety and efficacy data from all patients. More patients of Child-Pugh A received sorafenib for > 8 weeks than did patients of Child-Pugh B (55.5% vs. 34.3%). Child-Pugh score did not appear to influence the starting dose of sorafenib, and approximately 70% of patients both in Child-Pugh A and B groups received the recommended initial daily dose of 800 mg (69.0% and 69.5%, respectively). The median overall survival (OS) and time to progression (TTP) were 8.5 months and 2.5 months. In Child-Pugh A patients, the median OS and TTP were 10.2 months and 2.5 months. The most frequent treatment-emergent drug-related adverse event was hand-foot skin reaction (31.7%), followed by diarrhea (18.0%). The incidence of treatme...Continue Reading
References
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 20, 2008·The Lancet Oncology·Ann-Lii ChengZhongzhen Guan
Jul 21, 2010·International Journal of Clinical Practice·R LencioniM Kudo
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Mar 5, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN American Association for the Study of Liver Diseases
Jul 16, 2011·Journal of Hepatology·Valentina SantiFranco Trevisani
Mar 20, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver, UNKNOWN European Organisation For Research And Treatment Of Cancer
Jan 24, 2013·Journal of Clinical Gastroenterology·Kwang-Hyub HanChae Yoon Chon
Feb 14, 2013·The Journal of Contemporary Dental Practice·S Jayaprada ReddyG Vikram Reddy
Jun 1, 2012·Liver Cancer·Do Young Kim, Kwang-Hyub Han
Nov 29, 2013·International Journal of Clinical Practice·R LencioniA J Sanyal
Feb 15, 2015·Critical Reviews in Oncology/hematology·Kuo-Shyang JengChi-Juei Jeng
Citations
Nov 21, 2017·Clinical and Molecular Hepatology·Imane El Dika, Ghassan K Abou-Alfa
Sep 25, 2017·Oncotarget·Sung Hoon ChoiSeung Up Kim
Jun 26, 2020·Cancer Control : Journal of the Moffitt Cancer Center·Sun Hong YooJeong Won Jang
Mar 17, 2017·Targeted Oncology·Gillian M Keating
Dec 24, 2018·Expert Review of Anticancer Therapy·Bernard EscudierMasatoshi Kudo
Aug 17, 2018·JMIR Research Protocols·Nikhil ChauhanRiad Salem
Nov 11, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Pil Soo SungSi Hyun Bae
Dec 29, 2020·Journal of Hepatocellular Carcinoma·Sojung HanBeom Kyung Kim
Apr 25, 2021·Journal of Cancer Research and Clinical Oncology·Sojung HanBeom Kyung Kim
Jun 19, 2021·Translational Oncology·Francesca NegriCamillo Porta